GE HealthCare and Novo Nordisk have announced a collaboration to advance the development of peripheral focused ultrasound (PFUS) technology for the potential treatment of chronic diseases like type 2 diabetes and obesity. PFUS is a non-invasive form of bioelectronic medicine that uses ultrasound to stimulate the nervous system, with the aim of treating diseases. Initial research suggests that PFUS may impact glucose metabolism in people with diabetes through personalized ultrasound stimulation of nerve pathways.
Type 2 diabetes is a significant public health burden, affecting over 90 percent of people with diabetes worldwide. The collaboration between GE HealthCare and Novo Nordisk aims to further develop and validate the potential of PFUS as a non-pharmacologic approach to normalize blood glucose levels in people with type 2 diabetes and address unmet needs in these diseases.
GE HealthCare, a global medical technology company, will contribute its expertise in ultrasound medical technology, while Novo Nordisk, a leader in metabolic disease treatment and management, will bring its knowledge in this area to the collaboration. The ultimate goal is to create a PFUS solution that improves patient care. The terms of the agreement were not disclosed.
This collaboration represents an exciting step toward using ultrasound for therapeutic purposes and offers potential alternative treatment options for chronic diseases. The prevalence of type 2 diabetes and obesity is a significant global health concern, and innovative approaches like PFUS may hold promise for better disease management and treatment.
